Compared with simvastatin alone, human epidermal growth factor receptor-2 (HER2) peptide-pulsed DCs combined with simvastatin has better anti-tumor efficacy, and statin can enhance the anti-tumor function of the corresponding DC vaccine. Here, ERBB2 is linked to neoplasm.